] Shares Sigilon Therapeutics, Inc. Common Stock, par value $0.001 UNDERWRITING AGREEMENTUnderwriting Agreement • November 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and Jefferies LLC (together with Morgan Stanley, the “Representatives”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Sigilon Therapeutics, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including the Representatives (the “Underwriters”), of shares (the “Shares”) of the common stock, par value $0.001 per share, of the Company (the “Common Stock”).
SIGILON THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • November 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Sigilon Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
SIGILON THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (NON-EMPLOYEE DIRECTORS)Non-Statutory Stock Option Agreement • November 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Sigilon Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
SIGILON THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • November 30th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Sigilon Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
